HematologyNews.net

Hematology Xagena

Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia ( AML ) aged 65 or older and ineligible f ...


The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Eltrombopag in patients with severe aplastic anaemia who have had an insuff ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...


Intravenous Rituximab ( MabThera, Rituxan ) is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent Rituximab serum concentrations might improve conveni ...


Acute graft-versus-host disease ( GVHD ) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat ( Zolinza ) is an inhibitor of histone deac ...


Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints migh ...


Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in eld ...


Lenalidomide ( Revlimid ) has been linked to second primary malignancies in myeloma. Researchers have aimed to pool and analyse available data to compare the incidence of second primary malignancies i ...


Beta-thalassemias are characterized by ineffective red blood cell ( RBC ) production, leading to anemia, iron overload, and organ failure. As current treatment options for beta-thalassemia are limited ...


In acute lymphoblastic leukemia ( ALL ) response to therapy is usually measured by microscopic analysis of the bone marrow. The detection level for leukemic cells by this method is 5%. With molecular ...


A phase-I study for patients with chronic lymphocytic leukaemia has shown promising results. Chronic lymphocytic leukaemia ( CLL ) is the most common leukemia in adults in the Western world and is dia ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


The results of phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera were presented at the 50th Annual Meeting of the American Society of Clinical Oncology ( ASCO ). ...


Phosphatidylinositol-3-kinase delta ( PI3Kδ ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 ...


The monoclonal anti-CD20 antibody Rituximab ( MabThera, Rituxan ), combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreate ...


Acute lymphoblastic leukemia ( ALL ) is a rare type of blood cancer which is mainly treated by intensive chemotherapy. If the disease is resistant to initial treatment or reoccurs ( relapse ) the cha ...


Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with accep ...


Immobilization of the lower leg is associated with venous thromboembolism ( VTE ). Low molecular weight Heparin ( LMWH ) is an anticoagulant treatment which might be used in adult patients with lower- ...


The combination of lenalidomide ( Revlimid ) and Rituximab ( Rituxan ) has shown synergistic activity in chronic lymphocytic leukemia ( CLL ) preclinical models. In a CLL Research Consortium phase I ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati